Tirzepatid eddagala eriweweeza ku bulwadde bwa 20mg

▎ Enzimba ya Tirzepatid

Ensibuko: PubChem

Omutendera: Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{Aib}-Leu-Asp-Lys-Ile-Ala-Gln-{diaasidi-C20-gamm a-Glu-(AEEA)2-Lys}-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 Ensengekera ya molekyu: C 225H 348N 48O68 Obuzito bwa molekyu: 4813 g/mol Ennamba ya CAS: 2023788-19-2 Ekitongole kya PubChem CID: 163285897 Ebigambo ebifaanagana: Zepbound; Mounjaro nga bwe

▎ Okunoonyereza ku Tirzepatid

Kiki ekiva mu kunoonyereza ku Tirzepatid?

Ensibuko y’okunoonyereza ku Tirzepatid okusinga eva mu kunoonyereza ku ddagala erijjanjaba ssukaali n’obwetaavu bw’eddagala eriweweeza ku buzito. Eddagala ery’ekinnansi erijjanjaba ssukaali lirina obuzibu, ate nga GLP-1 receptor agonists liraga obulungi obw’amaanyi mu kulongoosa okufuga glucose mu musaayi, ekireetera abanoonyereza okukola eddagala erikola obulungi erya kiraasi y’emu. Nga GIP/GLP-1 dual receptor agonist, Tirzepatid esobola bulungi okulungamya emiwendo gya glucose mu musaayi. Okweyongera kw’abantu abagejjulukuka n’abagejjulukuka mu nsi yonna kifudde okufuga omugejjo obwetaavu obw’amangu mu bujjanjabi. GLP-1 receptor agonists zirina ebikolwa ebikendeeza ku buzito, ekizifuula ekigendererwa ky’okugejja. Tirzepatid efunye okufaayo olw’ebivaamu ebirungi mu kugejja.

Enkola ya Tirzepatid ekola ki?

Ekikolwa kya dual receptor agonist: 

Tirzepatid ye peptide-1 (GLP-1) eringa glucagon ey’emirundi ebiri ne glucose-dependent insulinotropic polypeptide (GIP) receptor agonist [1,2] (Wong E, 2023; Kumar D, 2022). GLP-1 ne GIP zombi busimu bwa incretin obukolebwa mu kyenda, nga bukola kinene nnyo mu kukuuma glucose homeostasis. Tirzepatid ekola ekikolwa eky’okukwatagana nga mu kiseera kye kimu ekola GLP-1 ne GIP receptors, bwe kityo n’etereeza emiwendo gya glucose mu musaayi.

Okulungamya okufulumya insulini ne glucagon: 

Kyongera ku kukola insulini n’okufulumya ate nga kikendeeza ku kufulumya glucagon mu ngeri eyeesigama ku glucose. Omuwendo gwa glucose mu musaayi bwe gulinnya, Tirzepatid asitula obutoffaali bwa β mu pancreatic okufulumya insulin, okutumbula okutwalibwa n’okukozesa glucose, bwe kityo ne kikendeeza ku glucose mu musaayi; mu kiseera kye kimu, kiziyiza obutoffaali bwa α-obutoffaali bw’olubuto okufulumya glucagon, okukendeeza ku glucose mu kibumba, okwongera okukendeeza ku glucose mu musaayi, n’okufuga obulungi emiwendo gya glucose mu musaayi mu kisiibo n’oluvannyuma lw’okulya ^[1,3]..

Enkola endala ez’okukola: 

Tirzepatid era etumbula okukkuta, ekiyinza okuba nga kyekuusa ku kukola ku GLP-1 receptors, okukola ku busimu obw’omu makkati, n’okukwata ku bifo ebifuga okwagala okulya, ekivaako abalwadde okukendeeza ku mmere gye balya era bwe kityo ne kiyamba mu kugejja. Era kilwawo okufulumya amazzi mu lubuto, ne kiwangaaza ekiseera emmere gy’emala mu lubuto n’okuyingira mpola mu kyenda ekitono, bwe kityo ne kiremesa emiwendo gya glucose mu musaayi okweyongera amangu ^[1]..

Ekifaananyi 1 Enkola y’okukola kwa T irzepatide ^[6]..

Biki ebikozesebwa mu kukozesa eddagala lya T irzepatide?

Obujjanjabi bwa sukaali ow’ekika eky’okubiri: 

Tirzepatid akkiriziddwa okujjanjaba abalwadde abakulu abalina ssukaali ow’ekika eky’okubiri ng’omugatte ku mmere n’okukola dduyiro. Okugezesebwa kwa SURPASS kwalaga nti Tirzepatid ekendeeza nnyo ku miwendo gya hemoglobin A1c (HbA1c), ng’okukendeeza kuva ku -1.87% okutuuka ku -2.59% (-20 okutuuka ku -28 mmol/mol). Era eraga okufuga kwa glycemic okusingako bw’ogeraageranya n’ebirungo ebimu ebiziyiza GLP-1 receptor, nga semaglutide 1 mg mu kugezesebwa kwa SUPRASS-2. Okugatta ku ekyo, esobola okukendeeza ku buzito bw’omubiri, ng’okugejja kuva ku kkiro -6.2 okutuuka ku -12.9 mu kunoonyereza ku bujjanjabi, ekintu ekikulu naddala eri abalwadde ba sukaali ow’ekika eky’okubiri abatera okuba n’ensonga z’omugejjo oba omugejjo ^[1,4]..

Obujjanjabi bw’omugejjo: 

Okuva Tirzepatid bw’eyamba okukkuta, ekendeeza ku mmere gy’alya, n’okutumbula okugejja, erina omugaso oguyinza okujjanjaba abalwadde abagejjulukuka. Okunoonyereza kulaga nti esobola okukendeeza ku buzito ebitundu ebisukka mu 20%, okulongoosa embeera y’omubiri gw’abalwadde, n’okukola ng’enkola empya ey’obujjanjabi eri omugejjo, okuyamba abalwadde abagejjulukuka okugejja n’okukendeeza ku bulabe bw’endwadde ez’enjawulo ezikwatagana n’omugejjo ^[1,2]..

Okukendeeza ku bulabe bw’okulwala endwadde z’emisuwa: 

Abalwadde ba sukaali ow’ekika eky’okubiri batera okwolekagana n’obulabe obw’okwongera okufuna endwadde z’emisuwa. Ng’oggyeeko okukendeeza ku ssukaali n’obuzito, Tirzepatid erina ebirungi ku bipimo ebikwata ku misuwa gy’omutima, omuli okukendeeza puleesa, okukendeeza ku masavu agakuŋŋaanyizibwa mu bitundu by’omubiri, n’okukendeeza ku miwendo gya triglyceride mu musaayi, bwe kityo n’ayamba okukendeeza ku bulabe bw’endwadde z’emisuwa n’okulongoosa ebiva mu misuwa gy’omutima ^[4]..

Obujjanjabi obuyinza okuweebwa obulwadde bwa steatohepatitis obutali bwa mwenge (NASH): 

Tirzepatid erina obusobozi bw’okujjanjaba NASH. Nga erongoosa insulin sensitivity n’okulungamya glucose ne lipid metabolism, esobola okukendeeza hepatic steatosis n’okuzimba, okuwa obulagirizi obupya eri NASH obujjanjabi ^[5]..

Mu bufunzi

Nga GIP/GLP-1 dual receptor agonist, Tirzepatid eraga nti ekola bulungi mu kujjanjaba ssukaali n’obuzibu mu nkyukakyuka y’emmere. Nga etereeza okufulumya insulini ne glucagon, okulwawo okufulumya amazzi mu lubuto, n’okutumbula okukkuta, kikendeeza bulungi ku muwendo gwa hemoglobin A1c n’okukendeeza ku buzito bw’omulwadde. Okugatta ku ekyo, eddagala lino lilongoosa ebintu ebiyinza okuleeta emisuwa ng’amasavu ne puleesa era liraga nti likola bulungi mu bulwadde bwa steatohepatitis obutali bwa mwenge.

Ebikwata ku Muwandiisi

Ebintu ebyogeddwako waggulu byonna binoonyerezeddwako, birongooseddwa era ne bikung’aanyizibwa kkampuni ya Cocer Peptides.

Omuwandiisi wa Scientific Journal

De Block C ekwatagana ne Yunivasite y’e Antwerp n’ebitongole ebikwatagana nabyo mu Bubirigi, omuli Inflamed Ctr Excellence, University Hospital Antwerp (UZA ne ​​Univ Hosp Antwerp), ne Infla Med Ctr Excellence. Okunoonyereza kwe kukwata ku bintu ebiwerako, gamba nga Endocrinology & Metabolism, ng’essira aliteeka ku busimu n’obuzibu mu nkyukakyuka y’emmere; Gastroenterology & Hepatology, okunoonyereza ku ndwadde z’okugaaya emmere n’ekibumba; General & Internal Medicine, ekola ku kuzuula n’okuddukanya endwadde z’omunda eza bulijjo; Nutrition & Dietetics, okunoonyereza ku ndya n’ebikosa obulamu; ne Urology & Nephrology, okunoonyereza ku pathology n’enkola y’obujjanjabi ku ndwadde z’omusulo n’ensigo. Mukenkufu alina emirimu mingi mu by’obusawo ebiwerako. De Block C ewandiikiddwa mu kiwandiiko ekijuliziddwa mu kiwandiiko ekijuliziddwa [4].

▎ Ebiwandiiko Ebikwatagana

[1] Wong E, Cope R, Dima L, n’abalala. Tirzepatid: Ekirungo kya Insulinotropic Polypeptide ekyesigama ku Glucose eky’emirundi ebiri ne Glucagon-Like Peptide-1 Agonist okuddukanya obulwadde bwa sukaali obw’ekika eky’okubiri[J]. Ekitabo ky’Amerika eky’obujjanjabi, 2023,30 (1):e26-e35.DOI:10.1097/MJT.0000000000001588.

[2] Kumar D, Harshidha D, Mousigan M, n’abalala. Okulambika ku Tirzepatid, Obujjanjabi obw’ebigendererwa bibiri ku Ssukaali n’Omugejjo[J]. Ekitabo ky’ensi yonna eky’okunoonyereza okuyiiya n’okukula, 2022,7:983.DOI:10.5281/zenodo.7420605.

[3] Sweta, Gupta S, Bansal S, n’abalala. Tirzepatid molekyu empya anti diabetic unfold ekikolwa eky’emirundi ebiri[J]. Zuula ebyobulamu by’abantu, 2024, 21 (1): 75.DOI: 10.1186 / s12982-024-00200-2.

[4] De Block C, Bailey C, Wysham C, n’abalala. Tirzepatid okujjanjaba abantu abakulu abalina sukaali ow’ekika eky’okubiri: Endocrine perspective[J]. Ssukaali Omugejjo & Enkyukakyuka mu mubiri, 2023, 25 (1): 3-17.DOI: 10.1111 / dom.14831.

[5] Sood A, Kaur P, Syed O, n’abalala. Enkyukakyuka mu kulabirira ssukaali: okulaga obusobozi bwa Tirzepatid mu kufuga glycemic n’okusingawo[J]. Omukugu mu kwekenneenya eddagala mu bujjanjabi, 2024, 17 (3): 235-246.DOI: 10.1080 / 17512433.2024.2310070.

[6] Grover-Páez F, Gómez A, Suárez A, n’abalala. Okuva ku nkola ya glycocentric mu mulwadde alina sukaali ow’ekika eky’okubiri okutuuka ku bujjanjabi obw’okuziyiza ebitundu ebingi n’okukendeera mu biva mu neuro-nephro-cardiovascular.[M]//2023.DOI: 10.5772/intechopen.1002363.

EBINTU BYONNNA N’AMAWULIRE GW’EBINTU EBIweereddwa KU MUTINDO GUNO BIKOZESEBWA KU KUSASANYA AMAWULIRE N’EBIKOLWA BY’OKUSOMESA.  

Ebintu ebiweereddwa ku mukutu guno bigendereddwamu kunoonyereza mu kisenge (in vitro research) byokka. Okunoonyereza mu vitro (Olulattini: *mu ndabirwamu*, ekitegeeza mu bikozesebwa mu ndabirwamu) kukolebwa ebweru w’omubiri gw’omuntu. Ebintu bino si bya ddagala, tebikkiriziddwa kitongole kya Amerika ekivunaanyizibwa ku by’emmere n’eddagala (FDA), era tebirina kukozesebwa kuziyiza, kujjanjaba oba kuwonya mbeera yonna ya bujjanjabi, bulwadde oba bulwadde. Kikugirwa nnyo mu mateeka okuyingiza ebintu bino mu mubiri gw’omuntu oba ebisolo mu ngeri yonna.